Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer

Osamu Ishimoto, Shunichi Sugawara, Akira Inoue, Takashi Ishida, Mitsuru Munakata, Sadahiro Koinumaru, Yukihiro Hasegawa, Toshiro Suzuki, Hiroshi Miki, Yasuo Saijo, Toshihiro Nukiwa

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

BACKGROUND: The combination of carboplatin and docetaxel has been considered one of the standard treatments for advanced non-small cell lung cancer (NSCLC). To investigate a safer and more convenient schedule for outpatient, we conducted a phase II study to evaluate the efficacy and the safety of carboplatin plus biweekly docetaxel for advanced NSCLC. PATIENTS AND METHODS: Patients with stage IIIB, IV, or postoperative recurrent NSCLC with good performance status were administered docetaxel at a dose of 35 mg/m on days 1 and 15 and carboplatin at an area under the curve (AUC) of 6 on day 1 every 4 weeks for at least three cycles. RESULTS: Fifty patients were treated with median of three cycles (range 1-6). Grade 3/4 toxicities included neutropenia in 18 patients (36%), thrombocytopenia in 4 patients (8%), and anemia in 10 patients (20%). No patient experienced febrile neutropenia. Nonhematological toxicities were also mild to moderate, and there were no treatment-related deaths. The overall response rate was 30%, and the disease control rate was 70%. Among the elderly population, 54% of patients achieved partial response. Median progression-free survival was 4.8 months, and median overall survival was 11.8 months. CONCLUSIONS: Biweekly docetaxel plus carboplatin has a similar efficacy and lower toxicity compared with a standard triweekly regimen of docetaxel plus carboplatin, which is a suitable regimen for outpatients, including elderly patients.

Original languageEnglish
Pages (from-to)979-983
Number of pages5
JournalJournal of Thoracic Oncology
Volume1
Issue number9
DOIs
Publication statusPublished - 2006 Nov

Keywords

  • Biweekly
  • Carboplatin
  • Chemotherapy
  • Docetaxel
  • Non-small cell lung cancer
  • Phase II trial

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this